



# Topotarget A/S

Conference call

**December 8, 2011**

Presenters:

Francois Martelet, CEO

Anders Vadsholt, CFO

# Safe harbour statement

This presentation may contain forward-looking statements, including statements about our expectations of the progression of our pre-clinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Topotarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that any one or more of the drug development programs of Topotarget A/S will not proceed as planned for technical, scientific, or commercial reasons or due to patient enrollment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; Topotarget's history of incurring losses and the uncertainty of achieving profitability; Topotarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against Topotarget's products, processes, and technologies; the ability to protect Topotarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability exposure. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

# Overview of reorganization

## Background:

- Second wave of adjusting Topotarget's employee headcount since April 2010, in accordance with the company's current strategy
- Topotarget entering a new phase of development, following an extended period of high workload in preparation of NDA-filing with the FDA of belinostat in PTCL, and finalization of the randomized phase II CUP trial

## Rationale for reorganization:

- Taking a proactive step in order to secure the company's own financing capabilities
- Reducing costs and strengthening financial foundation until expected significant milestone payments
- Enabling an adequate, cost-effective operational structure supporting the belinostat strategy



# Reorganization plan

## Main elements of reorganization in Topotarget

### Development focus

- Directing developmental efforts and investments into finalization of the PTCL pivotal study with belinostat and subsequent NDA filing with Spectrum Pharmaceuticals, Inc.
- Finalizing the CUP study (preparing top-line results)
- Continuing the clinical development of belinostat in solid tumor diseases and hematological cancer indications

### Current activities

- Investigating different strategic alternatives for our Totect-related operations in the US

### Organization

- Reducing the number of employees in Denmark by around 40%

# Reorganization plan (continued)

## Time-horizon

- The majority of the reorganization will take place in Q4 2011 and is expected fully implemented by H1 2012



## Implications of reorganization

- Topotarget maintains its development capabilities regarding the ongoing further development of belinostat in oncology
- Ongoing partnership with Spectrum Pharmaceuticals (PTCL BELIEF study) is not influenced by reorganization plans

# Financial implications and updated financial outlook

## Costs

- One-off costs related to the reorganization are estimated to total approx. DKK 4.1 million
- Of these costs, DKK 3.6 million are expected to be accounted for in Q4 2011, while the majority of the remaining one-off costs are expected to be accounted for in H1 2012
- Expected annual cost reductions projected to amount to DKK 9 million as from 2012

## Outlook

- Estimated pre-tax loss of DKK 25-45 million for FY 2011, compared to latest announced DKK 20-40 million
- Expected net cash and cash equivalents of around DKK 110 million by year-end 2011

# belinostat development is on track - PTCL

## PTCL – BELIEF study

- Registrational and pivotal study with 129 patients enrolled
- Study is jointly conducted, and sponsored by as well as finalized with partner, Spectrum Pharmaceuticals
- Primary study endpoint is objective response rate (ORR), with a required response rate of 20%
- Top-line data expected to be announced during 2012
- NDA submission to the FDA expected before end of 2012
- Expects to receive significant milestone payments from Spectrum related to the expected acceptance of an NDA filing, as well as the expected regulatory approval, respectively, by the FDA of belinostat for PTCL
- Following market launch, Topotarget will receive royalty payments from Spectrum



# belinostat development is on track - CUP

## CUP clinical study

- Randomized, controlled phase II study with enrollment of 89 patients completed, and is fully sponsored by Topotarget
- Currently collecting and cleaning data
- Primary endpoint is progression-free survival (PFS) with very high hurdle rate of 60%, as a result of the original study plans
- Secondary endpoints include overall survival (OS), ORR, time to response, duration of response, time to progression and safety
- Release of top-line data based on occurrence of PFS events is expected in H1 2012
- Based on the modest powering and design of the CUP study, it is not expected to serve as a registration study



# Overview of belinostat clinical trials 2011-2012

Indication	Study	Sponsor	Phase I	Phase II	Pivotal	Study size	Recruitment status	Milestone	Time
PTCL	BELIEF (CLN-19)	SPPI				129	Completed	NDA submission	2012
CUP	CLN-17	TT				89	Completed	Top-line results	H1 2012
Solid tumors	CLN-9	TT				92	Completed	Scientific publication	2012
Lymphoma	CLN-9	TT				28	Completed	Top-line results	H2 2011
Solid + STS	CLN-14	TT				~55	Phase I (25) Phase II (16)	Result phase I STS expansion Recruitment complete	H2 2011
Drug-drug	CLN-20	SPPI/TT				~39	Recruiting	n/a	n/a
NSCLC	SPI-1014 Bel	SPPI/TT				~35	Recruiting	n/a	n/a

# Conclusion

## Strengthened financial foundation

- Topotarget is operationally and cost-wise fully focused on the further development and capitalization of belinostat for the benefit of Topotarget's shareholders
- Taking a proactive step to secure own financing capabilities until expected milestone payments
- The company maintains its development capabilities regarding the ongoing further development of belinostat in oncology


## Outlook

- Estimated pre-tax loss of DKK 25-45 million for FY 2011, compared to latest announced DKK 20-40 million
- Expected net cash and cash equivalents of around DKK 110 million at year-end 2011

# Conclusion (continued)

Triggers expected to increase the value – a data-driven process

Illustrative



Note: Timelines are illustrative

# Contact information

**Francois Martelet**

*CEO*

+45 39 17 83 43 (phone)

+45 51 32 83 41 (cell)

[fma@topotarget.com](mailto:fma@topotarget.com)

**Anders Vadsholt**

*CFO*

+45 39 17 83 45 (phone)

+45 28 98 90 55 (cell)

[afv@topotarget.com](mailto:afv@topotarget.com)


**Topotarget A/S**

Fruebjergvej 3

DK-2100 Copenhagen



Company website:  
[www.topotarget.com](http://www.topotarget.com)



Q&A